Optimizing central nervous system drug development using molecular imaging

Clinical Pharmacology and Therapeutics

Volumn 98, Issue 1, 2015, Pages 47-60

  Hargreaves, R J ^a   Hoppin, J ^b   Sevigny, J ^a   Patel, S ^a   Chiao, P ^a   Klimas, M ^c   Verma, A ^a  

^a BIOGEN   (United States)

^b InviCRO LLC   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CENTRAL NERVOUS SYSTEM AGENTS; PHARMACOLOGICAL BIOMARKER;

ARTICLE; BLOOD BRAIN BARRIER; BOLD SIGNAL; COMPUTER ASSISTED TOMOGRAPHY; DEGENERATIVE DISEASE; DRUG INDUSTRY; DRUG MECHANISM; FLUORESCENCE IMAGING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMAGE RECONSTRUCTION; LATENT PERIOD; LIMIT OF DETECTION; MEDICAL CARE; MOLECULAR IMAGING; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PATIENT SELECTION; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOTOACOUSTICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REGISTRATION; SIGNAL NOISE RATIO; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DEPRIVATION; THERAPEUTIC INDEX; DRUG DEVELOPMENT; METABOLISM; PROCEDURES;

BIOMARKERS, PHARMACOLOGICAL; CENTRAL NERVOUS SYSTEM AGENTS; DRUG DISCOVERY; HUMANS; INDIVIDUALIZED MEDICINE; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84940561590     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.132     Document Type: Article

References (75)

1. De Masi J.A, Grabowski H.G, & Hansen R.W. Innovation in the pharmaceutical industry: new estimates of R&D costs. Tufts Center for the Study of Drug Development. http://csdd.tufts.edu/files/uploads/cost-study-backgrounder.pdf, and (2014).
2. Booth B. A billion here, a billion there. The cost of making a drug revisited. Forbes. (2014).
3. Kielstra P. The innovation imperative in biopharma. Reinventing biopharma strategies for an evolving marketplace. The Economist Intelligence Unit.
4. Matthews P.M. Preface - Imaging in CNS Drug Discovery and Development (eds. Borsook D, Becerra L, Bullmore E, & Hargreaves R.) v-vii (New York, Springer, 2009).
5. Frank R, & Hargreaves R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2, 566-580 (2003).
6. Hargreaves R, & Wagner J. Imaging as a biomarker for decision making in drug development. In vivo MR techniques in drug discovery and development (ed. Beckmann N.) 31-46 (New York, Taylor &Francis, 2006).
7. Hargreaves R.J. The role of molecular imaging in drug discovery and development. Clin. Pharmacol. Ther. 83, 349-353 (2008).
8. Rudin M, & Weissleder R. Molecular imaging in drug discovery and development. Nat. Rev. Drug Discov. 2, 123-131 (2003).
9. James M.L, & Gambhir S.S. A molecular imaging primer: modalities, imaging agents, and applications. Physiol. Rev. 92, 897-965 (2012).
10. Liu L, et al. Imaging the subcellular structure of human coronary atherosclerosis using micro-optical coherence tomography. Nat. Med. 17, 1010-1014 (2011).
11. Wang T.D, et al. Functional imaging of colonic mucosa with a fibered confocal microscope for real-Time in vivo pathology. Clin. Gastroenterol. Hepatol. 5, 1300-1305 (2007).
12. Isherwood B, et al. Live cell in vitro, and in vivo imaging applications: accelerating drug discovery. Pharmaceutics. 3, 141-170 (2011).
13. Patel M, Gleason A, O Malley S, Connolly B, et al. Correlation of ex vivo bioluminescence with quantitative histology. PLoS One. 9, 1-9 (2014).
14. Zackrisson S, van de Ven S.M, & Gambhir S.S. Light in, and sound out: emerging translational strategies for photoacoustic imaging. Cancer Res. 74, 979-1004 (2014).
15. Yao J, & Wang L.V. Photoacoustic brain imaging: from microscopic to macroscopic scales. Neurophotonics. 1, 011003-011013 (2014).
16. Bednar B, Zhang G.J, Williams D.L. Jr, Hargreaves R, & Sur C. Optical molecular imaging in drug discovery, and development. Expert Opin. Drug Discov. 2, 65-85 (2007).
17. Patel S, Hamill T, Hostetler E, Burns H.D, & Gibson R.E. An in vitro assay for predicting successful imaging radiotracers. Mol. Imaging Biol. 5, 65-71 (2003).
18. Patel S, et al. Screening cascade, and development of potential positron emission tomography radiotracers for mGluR5: in vitro and in vivo characterization. Mol. Imaging Biol. 7, 314-323 (2005).
19. Schwarz A.J, et al. A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #1: processes, and requirements. Drug Discov. Today. 16, 583-593 (2011).
20. Schwarz A.J, et al. A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #2: protocol optimization, and best practices. Drug Discov. Today. 16, 671-682 (2011).
21. Borsook D, Hargreaves R, & Becerra L. Can functional magnetic resonance imaging improve success rates in CNS drug discovery? Expert Opin. Drug Discov. 6, 597-617 (2011).
22. Schmidt M.E, et al. The influence of biological, and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data. Alzheimers Dementia; e-pub ahead of print 24 November 2014.
23. Chiao P, et al. Enrichment of early-stage AD patient recruitment to a Phase Ib study (221AD103) through amyloid PET screening by APOE 4 status. Oral presentation (abstract published) presented at: Alzheimer s Association International Conference, July 12-17, 2014, Copenhagen, Denmark. Alzheimers Dement. 10 (suppl.), P263-P264 (2014).
24. Sevigny J, et al. Randomized double bling phase 1b study (PRIME) of Aducanumab (BIIB037) an anti beta-Amyloid monoclonal antibody in subjects with prodromal or mild Alzheimer s disease. (Oral Presentation AD/PD Nice France, 2015).
25. Johnson K.A, et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 9 (suppl. 5), S72-S83 (2013).
26. Xia C.F, et al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer s disease. Alzheimers Dement. 9, 666-676 (2013).
27. Chien D.T, et al. Early clinical PET imaging results with the novel PHFtau radioligand [F-18]-T807. J. Alzheimers Dis. 34, 457-468 (2013).
28. Barthel H, Seibyl J, & Sabri O. The role of positron emission tomography imaging in understanding Alzheimer s disease. Expert Rev. Neurother. 15, 395-406 (2015).
29. Iannone R, et al. Acute alertness-promoting effects of a novel histamine subtype-3 receptor inverse agonist in healthy sleep-deprived male volunteers. Clin. Pharmacol. Ther. 88, 831-839 (2010).
30. Iannone R, et al. The relationship between brain receptor occupancy and alerting effects in humans support MK-0249, and MK-3134 as inverse agonists at the histamine subtype-3 pre-synaptic receptor. (Poster). American College of Neuropsychopharmacology (ANCP) 48th Annual Conference, Hollywood, Florida, December, 2009.
31. James L.M, et al. Effect of a novel histamine subtype-3 receptor inverse agonist, and modafinil on EEG power spectra during sleep deprivation, and recovery sleep in male volunteers. Psychopharmacology (Berl) 215, 643-653 (2011).
32. Hamill T.G, et al. Inverse Agonist Histamine H3 Receptor PET Tracers Labelled with carbon-11 or fluorine-18. Synapse. 63, 1122-1132 (2009).
33. Atack J.R, et al. MRK-409 (MK-0343), a GABAA receptor subtypeselective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans. J. Psychopharmacol. 25, 314-328 (2011).
34. Eng W, et al. Occupancy of human brain GABA(A) receptors by the novel a5 subtype-selective benzodiazepine site inverse agonist a5IA as measured using [11C]flumazenil PET imaging. Neuropharmacology. 59, 635-639 (2010).
35. Erondu N, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight, and obese adults. Cell Metab. 4, 275-282 (2006).
36. Burns H.D, et al. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinioid-1 receptor. Proc. Natl. Acad. Sci. USA. 104, 9800-9805 (2007).
37. Addy C, et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure, and decreasing caloric intake. Cell Metab. 7, 68-78 (2008).
38. Van Laere K, et al. Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J. Nucl. Med. 51, 1413-1417 (2010).
39. Liu P, et al. Discovery of MK-3168: a PET tracer for imaging brain fatty acid amide hydrolase. ACS Med. Chem. Lett. 4, 509-513 (2013).
40. Petrosino S, & Di Marzo V. FAAH, and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr. Opin. Investig. Drugs. 11, 51-62 (2010).
41. Bell I.M. Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine. J. Med. Chem. 57, 7838-7858 (2014).
42. Sinclair S.R, et al. Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974). Br. J. Clin. Pharmacol. 69, 15-22 (2010).
43. Bell I.M, et al. [(11)C]MK-4232: the first positron emission tomography tracer for the calcitonin gene-related peptide receptor. ACS Med. Chem. Lett. 4, 863-868 (2013).
44. Hostetler E.D, et al. In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232. J. Pharmacol. Exp. Ther. 347, 478-486 (2013).
45. Bigal M.E, & Walter S. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs. 28, 389-399 (2014).
46. Hargreaves R, et al. Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea, and vomiting. Ann. N Y Acad. Sci. 1222, 40-48 (2011).
47. Bergstr€om M, et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol. Psychiatry. 55, 1007-1012 (2004).
48. Van Laere K, et al. Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. Clin. Pharmacol. Ther. 92, 243-250 (2012).
49. Keller M, et al. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol. Psychiatry. 59, 216-223 (2006).
50. Michelson D, et al. Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder. Int. J. Neuropsychopharmacol. 16, 1-11 (2013).
51. Borsook D, Becerra L, & Hargreaves R. A role for fMRI in optimizing CNS drug development. Nat. Rev. Drug Discov. 5, 411-424 (2006).
52. Wise R.G, & Tracey I. The role of fMRI in drug discovery. J. Magn. Reson. Imaging. 23, 862-876 (2006).
53. Borsook D, Bleakman D, Hargreaves R, Upadhyay J, Schmidt K.F, Becerra L. A BOLD experiment in defining the utility of fMRI in drug development. Neuroimage. 42, 461-466 (2008).
54. Borsook D, Becerra L, Bullmore E, & Hargreaves R. The challenges, and opportunities. Imaging in CNS Drug Discovery and Development. (eds. Borsook D, Becerra L, Bullmore E, &Hargreaves R.) 3-9 (New York, Springer, 2009).
55. Borsook D, Becerra L, Bullmore E, & Hargreaves R. Reasons to believe: the potential of imaging in CNS drug development. 381-385 (eds. Borsook D, Becerra L, Bullmore E, & Hargreaves R.) Imaging in CNS Drug Discovery, and Development. (New York, Springer, 2009).
56. Hargreaves R.J, Becerra L, & Borsook D. Imaging as a CNS Biomarker. Biomedical Imaging: The Chemistry of Labels, Probes and Contrast Agents. (ed. Braddock M.) 411-440 (Cambridge, UK, The Royal Society of Chemistry, 2011).
57. Woodcock J, Witter J, & Dionne R.A. Stimulating the development of mechanism-based, individualized pain therapies. Nat. Rev. Drug Discov. 6, 703-710 (2007).
58. Borsook D, Hargreaves R, Bountra C, & Porecca F. Lost but making progress - where will new analgesic drugs come from? Sci. Transl. Med. 6, 249sr3 (2014).
59. Tracey I. Imaging pain. Br. J. Anaesth. 101, 32-39 (2008).
60. Wartolowska K, Hough M.G, Jenkinson M, Andersson J, Wordsworth B.P, & Tracey I. Structural changes of the brain in rheumatoid arthritis. Arthritis Rheum. 64, 371-379 (2012).
61. May A. Structural brain imaging: a window into chronic pain. Neuroscientist. 17, 209-220 (2011).
62. Howard M.A, et al. Beyond patient reported pain: perfusion magnetic resonance imaging demonstrates reproducible cerebral representation of ongoing post-surgical pain. PLoS One 6, e17096 (2011).
63. Borsook D, Becerra L, & Hargreaves R. Biomarkers for chronic pain, and analgesia. Part 1: the need, reality, challenges, and solutions. Discov. Med. 11, 197-207 (2011).
64. Borsook D, Becerra L, & Hargreaves R. Biomarkers for chronic pain, and analgesia. Part 2: how, where, and what to look for using functional imaging. Discov. Med. 11, 209-219 (2011).
65. Duff E.P, et al. Learning to identify CNS drug action, and efficacy using multistudy fMRI data. Sci. Transl. Med. 7, 274ra16 (2015).
66. Wager T.D, & Woo C.W. fMRI in analgesic drug discovery. Sci. Transl. Med. 7, 274fs6 (2015).
67. Hess A, et al. Blockade of TNF-A rapidly inhibits pain responses in the central nervous system. Proc. Natl. Acad. Sci. USA. 108, 3731-3736 (2011).
68. Zelaya F.O, et al. The response to rapid infusion of fentanyl in the human brain measured using pulsed arterial spin labelling. MAGMA. 25, 163-175 (2012).
69. Upadhyay J, et al. Modulation of CNS pain circuitry by intravenous and sublingual doses of buprenorphine. Neuroimage. 59, 3762-3773 (2012).
70. Upadhyay J, et al. Imaging drugs with, and without clinical analgesic efficacy. Neuropsychopharmacology. 36, 2659-2673 (2011).
71. Fowler J.S, & Volkow N.D. 18FDG for the study of central nervous system drugs. J. Clin. Pharmacol. Suppl, 9S-10S (2001).
72. Wang D.J, Chen Y, Fernández-Seara M.A, & Detre J.A. Potentials, and challenges for arterial spin labeling in pharmacological magnetic resonance imaging. J. Pharmacol. Exp. Ther. 337, 359-366 (2011).
73. Barkhof F, Haller S, & Rombouts S.A. Resting-state functional MR imaging: a new window to the brain. Radiology. 272, 29-49 (2014).
74. Lorenzi M, et al. Effect of memantine on resting state default mode network activity in Alzheimer s disease. Drugs Aging. 28, 205-217 (2011).
75. Kozauer N, & Katz R. Regulatory innovation, and drug development for early-stage Alzheimer s disease. N. Engl. J. Med. 368, 1169-1171 (2013).